Drug Development & ApprovalThe FDA recently cleared an amendment to the KB707 IND to evaluate inhaled KB707 to treat tumors in patient's lungs, representing a pioneering therapeutic approach in oncology.
Financial PerformanceKrystal's EPS for 4Q23 and FY23 surpassed analyst and consensus estimates, showcasing a stronger than expected financial performance.
Market AdoptionWith Vyjuvek's FDA approval and the addressing of patient scheduling issues, the drug is set for increased adoption, potentially leading to an upside in sales.